Puma Biotechnology, Inc. (NASDAQ:PBYI) Director Sells $90,990.00 in Stock

Puma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) Director Alessandra Cesano sold 27,000 shares of the firm's stock in a transaction that occurred on Friday, July 18th. The stock was sold at an average price of $3.37, for a total value of $90,990.00. Following the transaction, the director owned 41,850 shares of the company's stock, valued at $141,034.50. This trade represents a 39.22% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Alessandra Cesano also recently made the following trade(s):

• On Friday, June 13th, Alessandra Cesano sold 12,150 shares of Puma Biotechnology stock. The shares were sold at an average price of $3.40, for a total transaction of $41,310.00.

Puma Biotechnology Price Performance

Shares of PBYI traded down $0.12 on Friday, hitting $3.28. The company's stock had a trading volume of 300,286 shares, compared to its average volume of 336,143. The company has a market capitalization of $162.79 million, a PE ratio of 4.26 and a beta of 1.29. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.53 and a quick ratio of 1.43. Puma Biotechnology, Inc. has a fifty-two week low of $2.22 and a fifty-two week high of $4.13. The company has a 50 day moving average price of $3.44 and a 200 day moving average price of $3.19.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised shares of Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a report on Thursday, May 22nd.

Hedge Funds Weigh In On Puma Biotechnology

Several institutional investors have recently bought and sold shares of the business. Tower Research Capital LLC TRC grew its holdings in shares of Puma Biotechnology by 167.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 10,137 shares of the biopharmaceutical company's stock worth $31,000 after purchasing an additional 6,351 shares during the last quarter. CWM LLC lifted its position in Puma Biotechnology by 214.1% during the 2nd quarter. CWM LLC now owns 9,462 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 6,450 shares in the last quarter. Graham Capital Management L.P. acquired a new position in Puma Biotechnology during the 4th quarter worth about $33,000. ProShare Advisors LLC bought a new stake in Puma Biotechnology during the 4th quarter worth about $36,000. Finally, C2C Wealth Management LLC acquired a new stake in Puma Biotechnology in the 4th quarter valued at about $37,000. Institutional investors own 61.29% of the company's stock.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.